Terms: = Prostate cancer AND BCR, FLJ16453, 613, ENSG00000186716, BCR1, D22S662, D22S11, CML, P11274, PHL, ALL AND Treatment
653 results:
1. Comparing symptom clusters in cancer survivors by cancer diagnosis: A latent class profile analysis.
Lee LJ; Han CJ; Saligan L; Wallen GR
Support Care Cancer; 2024 Apr; 32(5):308. PubMed ID: 38662054
[TBL] [Abstract] [Full Text] [Related]
2. Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomy.
Yamada Y; Fujii Y; Kakutani S; Kimura N; Sugimoto K; Hakozaki Y; Sugihara T; Takeshima Y; Kawai T; Nakamura M; Kamei J; Taguchi S; Akiyama Y; Sato Y; Yamada D; Urabe F; Miyazaki H; Enomoto Y; Fukuhara H; Nakagawa T; Fujimura T; Kume H
Sci Rep; 2024 Mar; 14(1):7607. PubMed ID: 38556562
[TBL] [Abstract] [Full Text] [Related]
3. Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes.
Carbonell E; Mercader C; Sureda J; Gutiérrez A; Muñoz J; Gallardo E; Feltes N; Mases J; Valduvieco I; Vilaseca A; Franco A; Alcaraz A; Musquera M; Ribal MJ
World J Urol; 2024 Mar; 42(1):133. PubMed ID: 38478102
[TBL] [Abstract] [Full Text] [Related]
4. Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era.
Fletcher SA; Mamawala MM; Holler AE; Bhanji Y; Macura KJ; de la Calle CM; Pavlovich CP
Prostate; 2024 Jun; 84(8):723-730. PubMed ID: 38476030
[TBL] [Abstract] [Full Text] [Related]
5. Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH.
Guerrios-Rivera L; Janes JL; De Hoedt AM; Klaassen Z; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ; Fowke JH; Freedland SJ
Cancer Med; 2024 Feb; 13(4):e7012. PubMed ID: 38457188
[TBL] [Abstract] [Full Text] [Related]
6. The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.
Teppala S; Scuffham PA; Tuffaha H
Int J Technol Assess Health Care; 2024 Mar; 40(1):e14. PubMed ID: 38439629
[TBL] [Abstract] [Full Text] [Related]
7. Salvage Therapy for prostate cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical prostatectomy.
Morgan TM; Boorjian SA; Buyyounouski MK; Chapin BF; Chen DYT; Cheng HH; Chou R; Jacene HA; Kamran SC; Kim SK; Kirkby E; Luckenbaugh AN; Nathanson BJ; Nyame YA; Posadas EM; Tran PT; Chen RC
J Urol; 2024 Apr; 211(4):509-517. PubMed ID: 38421253
[TBL] [Abstract] [Full Text] [Related]
8. Salvage Therapy for prostate cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
Morgan TM; Boorjian SA; Buyyounouski MK; Chapin BF; Chen DYT; Cheng HH; Chou R; Jacene HA; Kamran SC; Kim SK; Kirkby E; Luckenbaugh AN; Nathanson BJ; Nyame YA; Posadas EM; Tran PT; Chen RC
J Urol; 2024 Apr; 211(4):526-532. PubMed ID: 38421252
[TBL] [Abstract] [Full Text] [Related]
9. Salvage Therapy for prostate cancer: AUA/ASTRO/SUO Guideline Part II: treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical prostatectomy.
Morgan TM; Boorjian SA; Buyyounouski MK; Chapin BF; Chen DYT; Cheng HH; Chou R; Jacene HA; Kamran SC; Kim SK; Kirkby E; Luckenbaugh AN; Nathanson BJ; Nyame YA; Posadas EM; Tran PT; Chen RC
J Urol; 2024 Apr; 211(4):518-525. PubMed ID: 38421243
[TBL] [Abstract] [Full Text] [Related]
10. Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.
Yin W; Chen G; Li Y; Li R; Jia Z; Zhong C; Wang S; Mao X; Cai Z; Deng J; Zhong W; Pan B; Lu J
Cancer Lett; 2024 Apr; 588():216739. PubMed ID: 38395379
[TBL] [Abstract] [Full Text] [Related]
11. A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.
Rade M; Kreuz M; Borkowetz A; Sommer U; Blumert C; Füssel S; Bertram C; Löffler D; Otto DJ; Wöller LA; Schimmelpfennig C; Köhl U; Gottschling AC; Hönscheid P; Baretton GB; Wirth M; Thomas C; Horn F; Reiche K
Mol Med; 2024 Feb; 30(1):19. PubMed ID: 38302875
[TBL] [Abstract] [Full Text] [Related]
12. Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.
Hu B; Zhang X; Zhu S; Wang C; Deng Z; Wang T; Wu Y
Eur J Med Res; 2024 Jan; 29(1):92. PubMed ID: 38297388
[TBL] [Abstract] [Full Text] [Related]
13. Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures.
Sweeney C; Gilsenan A; Calingaert B; Moeller C; Schomakers G; Sok A; Holzmann R; Pisa F
Pharmaceut Med; 2024 Mar; 38(2):145-156. PubMed ID: 38296916
[TBL] [Abstract] [Full Text] [Related]
14. Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retrospective analysis.
Watanabe K; Kamitani N; Ikeda N; Kawata Y; Tokiya R; Hayashi T; Miyaji Y; Tamada T; Katsui K
Brachytherapy; 2024; 23(2):179-187. PubMed ID: 38245406
[TBL] [Abstract] [Full Text] [Related]
15. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract] [Full Text] [Related]
16. Predictive Value of Preoperative prostate Health Index and Serum Testosterone Testing for Biochemical Recurrence after Radical prostatectomy for Non-Metastatic prostate cancer.
Zhang C; Zhang Y; Niu N; Fu G
Arch Esp Urol; 2023 Dec; 76(10):787-795. PubMed ID: 38186072
[TBL] [Abstract] [Full Text] [Related]
17. prostate cancer: Management of Biochemical Recurrence after Surgery.
Moreno-Olmedo E; Suárez-Gironzini V; Fusco JP; Ruiz L; Begara J; Guijarro M; González San Segundo C; Zafra J; López Campos F; Couñago F
Arch Esp Urol; 2023 Dec; 76(10):733-745. PubMed ID: 38186066
[TBL] [Abstract] [Full Text] [Related]
18. Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy.
Ozawa Y; Nohara S; Nakamura K; Hattori S; Yagi Y; Nishiyama T; Yorozu A; Monma T; Saito S
Prostate; 2024 Apr; 84(5):502-510. PubMed ID: 38173289
[TBL] [Abstract] [Full Text] [Related]
19. The Prognostic Role of Preoperative PSMA PET/CT in cN0M0 pN+ prostate cancer: A Multicenter Study.
Marra G; Rajwa P; Filippini C; Ploussard G; Montefusco G; Puche-Sanz I; Olivier J; Zattoni F; Moro FD; Magli A; Dariane C; Affentranger A; Grogg JB; Hermanns T; Chiu PK; Malkiewicz B; Kowalczyk K; Van den Bergh RCN; Shariat SF; Bianchi A; Antonelli A; Gallina S; Berchiche W; Sanchez-Salas R; Cathelineau X; Afferi L; Fankhauser CD; Mattei A; Karnes RJ; Scuderi S; Montorsi F; Briganti A; Deandreis D; Gontero P; Gandaglia G;
Clin Genitourin Cancer; 2024 Apr; 22(2):244-251. PubMed ID: 38155081
[TBL] [Abstract] [Full Text] [Related]
20. Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy.
Blas L; Shiota M; Tanegashima T; Tsukahara S; Ueda S; Mutaguchi J; Goto S; Kobayashi S; Matsumoto T; Inokuchi J; Eto M
Int J Urol; 2024 Apr; 31(4):404-408. PubMed ID: 38154806
[TBL] [Abstract] [Full Text] [Related]
[Next]
